EX-8 4 d410838dex8.htm EX-8 EX-8

Exhibit 8

Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries, associates and joint ventures as of March 31, 2017:

 

Name of the subsidiaries

    Country of
Incorporation		    Percentage of
Direct/Indirect Ownership Interest

Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.

    Malaysia    100%(3)

Aurigene Discovery Technologies Inc.

    U.S.A.    100%(3)

Aurigene Discovery Technologies Limited

    India    100%

beta Institut gemeinnützige GmbH

    Germany    100%(8)

betapharm Arzneimittel GmbH

    Germany    100%(8)

Cheminor Investments Limited

    India    100%

Cheminor Employees Welfare Trust

    India    Refer to footnote 18

Chienna B.V. (merged into Dr. Reddy’s Research and Development B.V. effective January 1, 2017)

    Netherlands    100%(13)

Chirotech Technology Limited

    United Kingdom    100%(5)

Dr. Reddy’s Research Foundation

    India    Refer to footnote 18

Dr. Reddy’s Farmaceutica Do Brasil Ltda.

    Brazil    100%

Dr. Reddy’s Laboratories (EU) Limited

    United Kingdom    100%(10)

Dr. Reddy’s Laboratories (Proprietary) Limited

    South Africa    100%(10)

Dr. Reddy’s Laboratories (UK) Limited

    United Kingdom    100%(5)

Dr. Reddy’s Laboratories Canada, Inc.

    Canada    100%(10)

Dr. Reddy’s Laboratories Inc.

    U.S.A.    100%(10)

Dr. Reddy’s Laboratories International SA

    Switzerland    100%(10)

Dr. Reddy’s Laboratories Japan KK

    Japan    100%(10)

Dr. Reddy’s Laboratories Kazakhstan LLP (from November 30, 2016)

    Kazakhstan    100%(10)

Dr. Reddy’s Laboratories Louisiana LLC

    U.S.A.    100%(6)

Dr. Reddy’s Laboratories New York, Inc.

    U.S.A.    100%(10)

Dr. Reddy’s Laboratories Romania S.R.L.

    Romania    100%(10)

Dr. Reddy’s Laboratories SA

    Switzerland    100%

Dr. Reddy’s Laboratories Tennessee, LLC

    U.S.A.    100%(6)

Dr. Reddy’s Laboratories, LLC

    Ukraine    100%(10)

Dr. Reddy’s New Zealand Limited.

    New Zealand    100%(10)

Dr. Reddy’s Pharma SEZ Limited

    India    100%

Dr. Reddy’s Singapore PTE Limited

    Singapore    100%(10)

Dr. Reddy’s Srl

    Italy    100%(11)

Dr. Reddy’s Bio-Sciences Limited

    India    100%

Dr. Reddy’s Laboratories (Australia) Pty. Limited

    Australia    100%(10)

Dr. Reddy’s Laboratories SAS

    Colombia    100%(10)

Dr. Reddy’s Research and Development B.V. (formerly Octoplus B.V.)

    Netherlands    100%(12)

Dr. Reddy’s Venezuela, C.A.

    Venezuela    100%(10)

DRANU LLC

    U.S.A.    50%(15)

DRES Energy Private Limited

    India    26%(16)

DRL Impex Limited

    India    100%(17)

DRSS Solar Power Private Limited

    India    26%(16) (2)

Eurobridge Consulting B.V.

    Netherlands    100%(1)

Idea2Enterprises (India) Pvt. Limited

    India    100%

Imperial Credit Private Limited (from February 22, 2017)

    India    100%

Industrias Quimicas Falcon de Mexico, S.A. de CV

    Mexico    100%

Kunshan Rotam Reddy Pharmaceutical Co. Limited

    China    51.33%(4)

Lacock Holdings Limited

    Cyprus    100%(10)

OctoPlus Development B.V. (merged into Dr. Reddy’s Research and Development B.V. effective January 1, 2017)

    Netherlands    100% (13)

Name of the subsidiaries

    Country of
Incorporation		    Percentage of
Direct/Indirect Ownership Interest

OctoPlus PolyActive Sciences B.V. (merged into Dr. Reddy’s Research and Development B.V. effective January 1, 2017)

    Netherlands    100% (14)

OctoPlus Sciences B.V. (merged into Dr. Reddy’s Research and Development B.V. effective January 1, 2017)

    Netherlands    100% (13)

OctoPlus Technologies B.V. (merged into Dr. Reddy’s Research and Development B.V. effective January 1, 2017)

    Netherlands    100% (13)

OctoShare B.V. (merged into Dr. Reddy’s Research and Development B.V. effective January 1, 2017)

    Netherlands    100% (13)

OOO Dr. Reddy’s Laboratories Limited

    Russia    100%(10)

OOO DRS LLC

    Russia    100%(9)

Promius Pharma LLC

    U.S.A.    100%(6)

Reddy Antilles N.V.

    Netherlands    100%

Reddy Cheminor S.A. (until July 20, 2016)

    France    100%(2)

Reddy Holding GmbH

    Germany    100%(10)

Reddy Netherlands B.V.

    Netherlands    100%(10)

Reddy Pharma Iberia SA

    Spain    100%

Reddy Pharma Italia S.R.L.

    Italy    100%(7)

Reddy Pharma SAS

    France    100%(10)

 

(1)

Indirectly owned through Reddy Antilles N.V.

(2)

Entities liquidated during the year.

(3)

Indirectly owned through Aurigene Discovery Technologies Limited.

(4)

Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company’s financial statements.

(5)

Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.

(6)

Indirectly owned through Dr. Reddy’s Laboratories Inc.

(7)

Indirectly owned through Lacock Holdings Limited.

(8)

Indirectly owned through Reddy Holding GmbH.

(9)

Indirectly owned through Eurobridge Consulting B.V.

(10)

Indirectly owned through Dr. Reddy’s Laboratories SA.

(11)

Indirectly owned through Reddy Pharma Italia S.R.L.

(12)

Indirectly owned through Reddy Netherlands B.V.

(13)

Indirectly owned through Dr. Reddy’s Research and Development B.V.

(14)

Indirectly owned through OctoPlus Sciences B.V.

(15)

DRANU LLC is consolidated in accordance with guidance available in IFRS 10.

(16)

Accounted in accordance with IFRS 11 ‘Joint Arrangements’.

(17)

Indirectly owned through Idea2Enterprises (India) Pvt. Limited.

(18)

The Company does not have any equity interests in this entity, but has significant influence or control over it.